| Anthony John Schena, MD | |
|
20 Guest St Ste 225, Brighton, MA 02135-2065 | |
| (617) 738-8642 | |
| (617) 202-4172 |
| Full Name | Anthony John Schena |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 27 Years |
| Location | 20 Guest St Ste 225, Brighton, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952398174 | NPI | - | NPPES |
| 2078635 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XX0005X | Orthopaedic Surgery - Sports Medicine | 158395 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vna Care Network | Worcester, MA | Home health agency |
| Nvna And Hospice | Norwell, MA | Home health agency |
| Partners Healthcare At Home - Home Care | Waltham, MA | Home health agency |
| Lahey Health At Home | Beverly, MA | Home health agency |
| Bayada Home Health Care, Inc | Providence, RI | Home health agency |
| New England Baptist Hospital | Boston, MA | Hospital |
| Emerson Hospital - | W concord, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Boston Orthopaedic And Spine Llc | 3476983909 | 18 |
| Massachusetts Institute Of Technology | 5597658666 | 51 |
News Archive
Sheba Medical Center at Tel HaShomer and Immunicom, Inc. are initiating a ground-breaking clinical trial to evaluate the clinical effectiveness of the Immunicom LW-02 plasma filtration device as a monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.
Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it has been added to the NASDAQ OMX Global Biotechnology Index (NASDAQ: QGBI). Component changes to the index occurred prior to the market open on September 21, 2009.
High levels of water hardness in the home may be linked to the development of eczema early in life, according to a new study led by King's College London.
Forest Laboratories, Inc. announced today that Daliresp was approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of chronic obstructive pulmonary disease exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
› Verified 2 days ago
| Entity Name | Massachusetts Institute Of Technology |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346308723 PECOS PAC ID: 5597658666 Enrollment ID: O20040203000789 |
News Archive
Sheba Medical Center at Tel HaShomer and Immunicom, Inc. are initiating a ground-breaking clinical trial to evaluate the clinical effectiveness of the Immunicom LW-02 plasma filtration device as a monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.
Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it has been added to the NASDAQ OMX Global Biotechnology Index (NASDAQ: QGBI). Component changes to the index occurred prior to the market open on September 21, 2009.
High levels of water hardness in the home may be linked to the development of eczema early in life, according to a new study led by King's College London.
Forest Laboratories, Inc. announced today that Daliresp was approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of chronic obstructive pulmonary disease exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
› Verified 2 days ago
| Entity Name | Pro Sports Orthopedics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518971811 PECOS PAC ID: 1153394796 Enrollment ID: O20040812001584 |
News Archive
Sheba Medical Center at Tel HaShomer and Immunicom, Inc. are initiating a ground-breaking clinical trial to evaluate the clinical effectiveness of the Immunicom LW-02 plasma filtration device as a monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.
Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it has been added to the NASDAQ OMX Global Biotechnology Index (NASDAQ: QGBI). Component changes to the index occurred prior to the market open on September 21, 2009.
High levels of water hardness in the home may be linked to the development of eczema early in life, according to a new study led by King's College London.
Forest Laboratories, Inc. announced today that Daliresp was approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of chronic obstructive pulmonary disease exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
› Verified 2 days ago
| Entity Name | Pro Sports Orthopedics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659829323 PECOS PAC ID: 8123301173 Enrollment ID: O20170216002809 |
News Archive
Sheba Medical Center at Tel HaShomer and Immunicom, Inc. are initiating a ground-breaking clinical trial to evaluate the clinical effectiveness of the Immunicom LW-02 plasma filtration device as a monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.
Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it has been added to the NASDAQ OMX Global Biotechnology Index (NASDAQ: QGBI). Component changes to the index occurred prior to the market open on September 21, 2009.
High levels of water hardness in the home may be linked to the development of eczema early in life, according to a new study led by King's College London.
Forest Laboratories, Inc. announced today that Daliresp was approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of chronic obstructive pulmonary disease exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
› Verified 2 days ago
| Entity Name | Boston Orthopaedic And Spine Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619507043 PECOS PAC ID: 3476983909 Enrollment ID: O20200423001231 |
News Archive
Sheba Medical Center at Tel HaShomer and Immunicom, Inc. are initiating a ground-breaking clinical trial to evaluate the clinical effectiveness of the Immunicom LW-02 plasma filtration device as a monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.
Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it has been added to the NASDAQ OMX Global Biotechnology Index (NASDAQ: QGBI). Component changes to the index occurred prior to the market open on September 21, 2009.
High levels of water hardness in the home may be linked to the development of eczema early in life, according to a new study led by King's College London.
Forest Laboratories, Inc. announced today that Daliresp was approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of chronic obstructive pulmonary disease exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anthony John Schena, MD 20 Guest St Ste 225, Brighton, MA 02135-2065 Ph: (617) 738-8642 | Anthony John Schena, MD 20 Guest St Ste 225, Brighton, MA 02135-2065 Ph: (617) 738-8642 |
News Archive
Sheba Medical Center at Tel HaShomer and Immunicom, Inc. are initiating a ground-breaking clinical trial to evaluate the clinical effectiveness of the Immunicom LW-02 plasma filtration device as a monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.
Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it has been added to the NASDAQ OMX Global Biotechnology Index (NASDAQ: QGBI). Component changes to the index occurred prior to the market open on September 21, 2009.
High levels of water hardness in the home may be linked to the development of eczema early in life, according to a new study led by King's College London.
Forest Laboratories, Inc. announced today that Daliresp was approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of chronic obstructive pulmonary disease exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
› Verified 2 days ago
Dr. Diane M. English, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 11 Nevins St, Suite 403, Brighton, MA 02135 Phone: 671-254-1247 Fax: 617-787-9246 | |
Raymond A Sullivan Jr., M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 11 Nevins St. Suite 303, St. Elizabeth's Med Blg, Brighton, MA 02135 Phone: 617-787-2308 | |
Dr. Sarav Shah, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 20 Guest St Ste 225, Brighton, MA 02135 Phone: 617-738-8642 Fax: 617-202-4172 | |
Lester J. Sheehan Jr., MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 77 Warren St, Brighton, MA 02135 Phone: 617-562-5525 Fax: 617-562-5546 | |
Glen Ross, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 20 Guest St, Ste 225, Brighton, MA 02135 Phone: 617-738-8642 Fax: 617-202-4172 | |
Matthew Michael Werger, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 20 Guest St Ste 225, Brighton, MA 02135 Phone: 617-738-8642 Fax: 617-202-4172 | |
Michael Doyle Mason, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 20 Guest St, Suite 225, Brighton, MA 02135 Phone: 617-738-8642 Fax: 617-491-2552 |